Beta Bionics (NASDAQ:BBNX) Director Sells $39,354.00 in Stock

Beta Bionics, Inc. (NASDAQ:BBNX) Director Christy Jones sold 2,811 shares of the business’s stock in a transaction that occurred on Thursday, June 4th. The stock was sold at an average price of $14.00, for a total value of $39,354.00. Following the transaction, the director directly owned 27,400 shares in the company, valued at $383,600. The trade was a 9.30% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Christy Jones also recently made the following trade(s):

• On Thursday, May 21st, Christy Jones sold 1,998 shares of Beta Bionics stock. The stock was sold at an average price of $9.95, for a total value of $19,880.10.

Beta Bionics Stock Performance

BBNX stock opened at $13.89 on Monday. The firm has a market capitalization of $618.94 million, a PE ratio of -9.20 and a beta of 3.40. Beta Bionics, Inc. has a 1-year low of $8.80 and a 1-year high of $32.71. The business’s 50 day simple moving average is $10.93 and its 200 day simple moving average is $17.12.

Beta Bionics (NASDAQ:BBNX) last posted its earnings results on Tuesday, April 21st. The company reported ($0.49) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.53) by $0.04. The business had revenue of $27.63 million for the quarter. Beta Bionics had a negative return on equity of 23.00% and a negative net margin of 60.27%. As a group, sell-side analysts predict that Beta Bionics, Inc. will post -2.19 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Perceptive Advisors LLC grew its holdings in Beta Bionics by 39.8% in the 1st quarter. Perceptive Advisors LLC now owns 842,944 shares of the company’s stock valued at $8,446,000 after buying an additional 240,000 shares in the last quarter. Eversept Partners LP grew its holdings in Beta Bionics by 108.6% in the 1st quarter. Eversept Partners LP now owns 1,414,838 shares of the company’s stock valued at $14,177,000 after buying an additional 736,576 shares in the last quarter. Quantinno Capital Management LP grew its holdings in Beta Bionics by 112.9% in the 1st quarter. Quantinno Capital Management LP now owns 67,879 shares of the company’s stock valued at $680,000 after buying an additional 35,996 shares in the last quarter. Lazard Asset Management LLC acquired a new position in Beta Bionics in the 1st quarter valued at $720,000. Finally, Granahan Investment Management LLC grew its holdings in Beta Bionics by 104.9% in the 1st quarter. Granahan Investment Management LLC now owns 248,449 shares of the company’s stock valued at $2,489,000 after buying an additional 127,203 shares in the last quarter.

Analyst Ratings Changes

BBNX has been the topic of a number of recent analyst reports. Lake Street Capital set a $20.00 target price on Beta Bionics in a report on Wednesday, February 18th. Stifel Nicolaus decreased their target price on Beta Bionics from $22.00 to $20.00 and set a “buy” rating on the stock in a report on Wednesday, April 22nd. Bank of America decreased their target price on Beta Bionics from $23.00 to $11.00 and set a “neutral” rating on the stock in a report on Monday, May 18th. Wall Street Zen lowered Beta Bionics from a “hold” rating to a “sell” rating in a report on Sunday, March 29th. Finally, Weiss Ratings lowered Beta Bionics from a “sell (d-)” rating to a “sell (e+)” rating in a report on Tuesday, April 21st. One investment analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, three have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, Beta Bionics currently has an average rating of “Moderate Buy” and an average price target of $19.70.

Beta Bionics Company Profile

Beta Bionics, a clinical-stage medical device company headquartered in Boston, Massachusetts, is focused on revolutionizing the management of type 1 diabetes through automated insulin delivery solutions. The company’s flagship product, the iLet Bionic Pancreas system, is designed to simplify glycemic control by automatically adjusting insulin dosing in response to continuous glucose monitoring data. By integrating advanced algorithmic control with wearable infusion pumps, the iLet aims to reduce the daily burden of diabetes management and improve clinical outcomes for patients.

At the core of Beta Bionics’ offering is its proprietary bionic pancreas software, which can operate in both insulin-only and dual‐hormone modes.